Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic

  • STATUS
    Recruiting
  • participants needed
    1200
  • sponsor
    Centre Hospitalier Intercommunal Creteil
Updated on 16 February 2024
fibrosis
covid-19
cystic fibrosis
cftr gene

Summary

Impacts of the Covid-19 epidemic and associated lockdown measures on the management, health and behaviors of cystic fibrosis patients during the 2020 epidemic

Description

The containment of the population in France is a health measure implemented in response to SARS-CoV-2 (Covid-19) infection. For cystic fibrosis, as for many chronic diseases, this disruption is twofold. On the one hand, it affects daily life due to the closure of schools and the introduction of national lockdown, but also the hospital, which has profoundly changed its procedures, which are almost completely focused on the care of patients with Covid-19. This forced transformation was at the expense of its usual role including the management of chronic diseases such as cystic fibrosis. It has an impact on patients' consultations cancelled, rescheduled or replaced by teleconsultations, hospitalisations whether scheduled or during acute exacerbations which are more complicated to organise. Access to treatments is also more difficult (physiotherapy), which can affect compliance. Confinement also profoundly changes the lives of our patients. It changes the way individuals can apprehend their disease and its integration into their everyday life, studies or professional projects. Finally, it is the confrontation with a potentially fatal infection that reminds us of the risks and consequences of a potentially severe chronic disease.

Details
Condition Pulmonary Disease, Cystic Fibrosis, Cystic Fibrosis, Pancreatic disorder, Cystic Fibrosis in Children
Age 14years - 100years
Treatment Interview, Questionnaire
Clinical Study IdentifierNCT04463628
SponsorCentre Hospitalier Intercommunal Creteil
Last Modified on16 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient with cystic fibrosis (Southern Chlorine > 60 mEq/L and/or presence of 2 pathogenic mutations on the CFTR gene)
Supported in a French CRCM (Cystic fibrosis Resource and Competence Center)
Affiliated to a social security scheme
Non-opposition for participation in the protocol

Exclusion Criteria

Minor patient under 14 years of age
Computer equipment or internet connection defect
Clear my responses

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.